This article is more than 5 years old. Information may no longer be current.
UPCI appoints program co-director
Click Here to Manage Email Alerts
James Herman, MD, has been named co-leader of the University of Pittsburgh Cancer Institute’s lung cancer program.
Herman, a leader in the field of epigenetics who served on the faculty at Johns Hopkins Medicine since 1996, also will hold the title of visiting professor of medicine in the division of hematology/oncology at Pitt’s School of Medicine. His appointment will be effective Nov. 1.
“Jim is a senior scientist who brings extensive experience to UPCI,” Nancy E. Davidson, MD, director of UPCI and the UPMC Cancer Center, said in a press release. “He will assume leadership of the UPCI Lung Cancer SPORE grant and work closely with [Mark A. Socinski, MD] in our lung cancer program, strengthening an already impressive team.”
James Herman
Herman — whose research led to the development of the methylation-specific PCR assay, used to characterize DNA methylation patterns — is expected to have an appointment at the VA Hospital in Pittsburgh, where he will promote clinical care, education and clinical trials in thoracic malignancies.
He also will serve as co-director of the medical oncology fellowship program to promote training in basic and translational research.